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Background: Coronary artery bypass grafting using the radial artery has, since the 1990s, gone through a revival.
Observational studies have indicated better long-term patency when using radial arteries. Therefore, radial artery
might be preferred especially in younger patients where long time patency is important. During the last 10 years
different endoscopic techniques to harvest the radial artery have evolved. Endoscopic radial artery harvest only
requires a small incision near the wrist in contrast to open harvest, which requires an incision from the elbow to
the wrist. However, it is unknown whether the endoscopic technique results in fewer complications or a graft
patency comparable to open harvest. When the radial artery has been harvested, there are two ways to use the
radial artery as a graft. One way is sewing it onto the aorta and another is sewing it onto the mammary artery. It is
unknown which technique is the superior revascularisation technique.
Methods/Design: The NEO Trial is a randomised clinical trial with a 2 × 2 factorial design. We plan to randomise
300 participants into four intervention groups: (1) mammario-radial endoscopic group; (2) aorto-radial endoscopic
group; (3) mammario-radial open surgery group; and (4) aorto-radial open surgery group.
The hand function will be assessed by a questionnaire, a clinical examination, the change in cutaneous sensibility,
and the measurement of both sensory and motor nerve conduction velocity at 3 months postoperatively. All the
postoperative complications will be registered, and we will evaluate muscular function, scar appearance, vascular
supply to the hand, and the graft patency including the patency of the central radial artery anastomosis. A patency
evaluation by multi-slice computer tomography will be done at one year postoperatively.
We expect the nerve conduction studies and the standardised neurological examinations to be able to discriminate
differences in hand function comparing endoscopic to open harvest of the radial artery. The trial also aims to show
if there is any patency difference between mammario-radial compared to aorto-radial revascularisation techniques
but this objective is exploratory.
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Current treatment
In coronary bypass surgery, a vein or artery graft is used to
lead the blood past the stenosis that gives rise to the
symptoms of the patient. This graft can be taken from the
chest, leg, or arm. The left internal mammary artery
(LIMA), which is situated on the inside of the chest wall,
is the most commonly used graft. This graft has the best
patency and is often used as a bypass to the anterior de-
scending coronary artery (LAD) situated on the front left
side of the heart. The saphenous vein from the leg is often
the second choice. It is technically easy to harvest and it is
long, allowing for multiple grafts. Another possibility is
using the radial artery, which might have a better long-
term patency than the saphenous vein. It is much shorter
in length and therefore it can be difficult to reach all the
coronary arteries required for a bypass graft.
The radial artery graft has in some studies shown
a short-term patency of about 86% to 91% [1-3] and a
long-term patency of about 81% to 89% [3-7]. Also, a
lower short-time patency of 81% to 86% has been shown
when using the saphenous vein grafts [4,8]. However, one
of these studies had conflicting results [8]. In a cohort
study of 925 patients, saphenous vein graft recipients had
a significantly higher mortality than radial artery graft
recipients 0 to 6 years after bypass surgery [9]. Guidelines
on myocardial revascularisation recommend using total
arterial revascularisation in patients with a substantial
post-operative life expectancy [10].Clinical data on the experimental interventions
Endoscopic vessel harvesting was first introduced in the
mid-1990s, where the procedure was used to harvest the
saphenous vein. By 2005, it was recognised as the pro-
cedure of choice [11] and it is now used in about 80% of
patients at US hospitals. Between 2001 and 2004, three
case studies describing endoscopic radial artery harvest
(ERAH) were published [12-14].Complications after radial artery harvest
The largest case-control study of ERAH reported fewer
complications compared to open surgery [15]. Other
studies have shown the same, including a significant de-
crease in other complications such as haematomas andinfections [16-18]. So far, only one randomised clinical
trial dealing with postoperative neurological deficits and
pain has been published [19]. This trial (n = 50) reported
fewer neurological complications (11 (44%) in the ERAH
group versus 17 (85%) in the open radial artery harvest
(ORAH) group; P = 0.23) and a significantly lower num-
ber of severe neurological complications (score of 1–5
points, 0.8 ± 1.1 in ERAH group versus 2.2 ± 1.2 in
ORAH group; P < 0.001) when assessed by telephone in-
terviews of self-reported complications.
The reported rate of neurological complications after
ORAH is about 11% to 39% [20-23]. The highest preva-
lence was found in the study by Dick et al., where 39%
of the patients had self-reported persistent discomfort at
the arm at a mean of 0.9 years postoperatively (numb-
ness (32%), paraesthesia or dysesthesia (14%), pain (5%))
[22]. In three out of the four studies, more than 30% of
patients had a self-reported neurological deficit.
ERAH reduced the risk of neurological complications
in one prospective cohort study from 10% to 0% [17].
The largest published series of ERAH from Connolly
et al. reported a complication rate of about 10%, but the
sensitivity to detect complications was limited by the
follow-up being done by telephone interview or office
visit alone with no objective clinical examination [13].
The published studies differ in how the investigators
examine the extent of neurological deficits. Most use
non-specific neurological examinations and others only
rely on questionnaires [24]. The most specific examin-
ation procedure seems to be used by Bleiziffer et al.,
who assessed the muscle strength, deep tendon reflexes,
temperature, pain, and touch sensation [18].Patency in endoscopic harvested graft material
Three large observational studies of short-term patency
in endoscopic harvested veins has questioned the pa-
tency when using the endoscopic technique (EVH) com-
pared to the open technique (OVH) [25-27]. All three
studies reported lower vein graft patency and one of
them even a higher mortality when using EVH. On the
contrary, most other database studies have not shown a
higher mortality after EVH than after OVH [28-31]. The
latest retrospective cohort study included an unpre-
cedented 235,000 patients and showed no difference in
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[32]. It has been proposed that the possible reasons for a
lower patency in EVH might be trauma to the vessel
during endoscopic harvest and thermic spread from the
ligating device, but most studies of graft histology and
function have shown no difference resulting from the
techniques used [33].
The patency in ERAH versus ORAH could be ques-
tioned. Three studies have dealt with patency differences
comparing open surgery with the endoscopic technique.
One study appraised the patency assessed by 64 multi-
slice CT (MSCT) in 33 patients and by angiography in
17 patients and found no difference [34]. Two other
studies included 94 patients undergoing 16 slice MSCT
and 95 patients undergoing either angiography or CT-
scan, respectively, before discharge [16,35]. Neither of
the studies reported a difference in the short-term pa-
tency. None of the patency studies have used a rando-
mised clinical trial design. As with the EVH studies, the
studies using radial artery grafts have reported no differ-
ence in histology or function [36,37].Composite grafting
When using the radial artery graft it is possible to anas-
tomose it either directly onto the aorta (aorto-radial/
free radial) or onto the side of the LIMA (mammario-
radial/Y-graft) as a so-called composite graft. Different
techniques of using the radial artery graft as a compos-
ite graft are well described [38-40]. One retrospective
cohort study showed a higher risk of string-sign and a
lower patency when comparing composite grafting with
individual grafting [41]. This was only related to target
vessels with mild stenosis. Another large retrospective
case-control study of 893 patients showed a lower pa-
tency in composite grafts compared to direct aortic
grafts [42]. Other studies have shown the site of the
proximal anastomosis to be without any influence on
the resulting patency [43-45]. With composite grafting
it is possible to perform a greater number of distal cor-
onary anastomoses and the proximal anastomosis does
not require aortic partial clamping, which may increase
the risk of cerebral embolism. A retrospective study
showed a non-significant difference in patency between
composite grafts (T-graft) and free radial grafts [46].
One randomised clinical trial comparing patency after
mammario-radial grafting showed a significantly better
clinical outcome and better patency in the radial artery
composite graft group [47,48]. Another randomised
clinical trial (Stand-in-Y Mammary Study) compared
the right internal mammary artery as a Y-graft versus ra-
dial artery as a free graft and showed a significantly bet-
ter survival when revascularisation was done with two
arteries compared to one artery [49].Trial objectives
The NEO trial 1
The primary objective will be to assess ERAH versus
ORAH on:
 The hand function, assessed by a questionnaire.
The secondary objectives will be to assess ERAH versus
ORAH on:
 Postoperative neurological deficits using nerve
conduction studies.
 Postoperative neurological deficits using clinical
examination of motor function and quantitative
sensory testing.
 Differences in complications (ischemia, infections,
wound dehiscence, haematoma formation, etc.).
Further, the exploratory objectives will be to assess
ERAH versus ORAH on:
 Serious adverse events.
 The postoperative scar.
 Postoperative handgrip strength.
 Postoperative muscle function.
 Hand function questionnaire single items.
 Neurological deficits single test.
 Graft patency.
 Postoperative pain in the donor arm.
 Examination of the vascular supply to the hand
after radial artery harvest.
The NEO trial 2
The primary objective will be to assess mammario-radial
versus aorto-radial grafting on:
 The composite cerebrovascular outcome of cerebral
stroke, postoperative revascularisation, myocardial
infarction, or all-cause mortality.
The secondary objective will be to assess mammario-
radial versus aorto-radial grafting on:
 Graft patency evaluated by MSCT.
Methods and design
Design and randomisation procedure
The NEO trial will be a randomised clinical trial
using the 2 × 2 factorial trial design with a partly
blinded outcome assessment. We assume that there
is no interaction between the interventions being
assessed.
The Copenhagen Trial Unit will conduct central web-
based randomisation. All participants will be randomised
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ing surgery (CABG) surgery. Approximately 150 patients
will be allocated to the ERAH group and approximately
150 patients to the ORAH group (the NEO trial 1). The
two groups will furthermore be randomised into two
groups of 75 patients each. The two groups will differ in
how the radial artery is proximally anastomosed to either
the aorta or to the LIMA (the NEO trial 2). In all, there
will be approximately 150 patients with an aorto-radial
anastomosis and approximately 150 patients with a
mammario-radial anastomosis. The allocation sequence
will be a computer-generated using varying block sizes
and will be concealed to the investigators. The randomisa-
tion will be stratified by age (age up to 59 years compared
to 60 years or older) and sex.
The trial flow chart can be seen in Figure 1.Figure 1 Trial flow chart.Selection of participants
All non-acute patient referrals to the Department of
Cardio-thoracic Surgery, Rigshospitalet, University Hospital
of Copenhagen, Denmark, will be screened for eligibility.
Approximately 6,000 patients will be screened. Patients will
be eligible for the NEO trial, if they fulfil the following in-
clusion criteria and if they do not fulfil any exclusion
criteria.
Inclusion and exclusion criteria
Inclusion criteria
 Elective or subacute coronary artery bypass graft as
an isolated procedure.
 Age >18 years.
 Coronary multi-vessel disease.
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 Written informed consent.
Exclusion criteria
 Geographically not available for follow-up.
 Modified Allen’s test indicating insufficient ulnary
artery perfusion.
 Valve surgery, ablation surgery, or any kind of
concomitant surgery during same admission.
 Acute operation (<24 hours from admission).
 Dialysis.
 Preoperative neurological deficit on the donor arm.
 Left ventricular ejection fraction <20%
preoperatively.
 Prior sternotomy.
 Allergy to contrast medium.
 Malignant disease.
 No written informed consent.
Preoperatively, all patients will have a modified Allen’s
test performed to ensure sufficient vascular function of the
ulnary artery. A modified Allen’s test is defined as a normal
capillary response in the hand in less than 7 to 10 seconds
after relief of digital compression of the ulnar artery during
a strong fist grip emptying the hand of blood [50].
Blinding
The patients and surgeons cannot be blinded to the inter-
vention used, as it will be obvious to both patient and
surgeon whether the radial artery has been harvested
with endoscopic or open techniques. Likewise, neither
the patients nor the surgeons can be blinded to which
proximal anastomotic site is used, since the surgeon will
be performing the anastomosis and the patient has the
right to be informed about the procedure performed.
The neurophysiology technicians cannot be blinded to
whether ERAH or ORAH has been used since the neuro-
physiological examination requires placing electrodes near
the scar evidently showing which procedure was used.
The NEO trial nurse cannot be blinded since she will be
aware of screening, randomisation, and outcome measure-
ments of the individual patients.
The clinical staff examining handgrip strength and muscle
function will be blinded to which intervention has been used.
The staff interpreting the MSCTs cannot be blinded in
consideration to the NEO trial 2 but will be blinded in
consideration to the NEO trial 1.
The data collection will be blinded when using register
data.
The statistical analysis of the trial will be blinded with
the intervention groups coded as, e.g., ‘X’ and ‘Y’, follow-
ing which two conclusions will be drawn: one assuming
‘X’ is the experimental group and ‘Y’ is the controlgroup, and one conclusion assuming the opposite. After
this, the blinding will be broken.
As to the specific blinding of outcomes see the section
‘Assessment of outcomes’.
Trial interventions
The non-dominant arm will always be preferred. This
will be determined by self-reporting from the patient.
The occurrence of neurological damage in the dominant
arm can severely impair the patient’s function postopera-
tively and therefore harvesting of the radial artery in the
dominant arm will not be done.
The NEO trial 1
The unpublished department routines for operative tech-
niques used on the donor arm are described in Table 1.
After harvest the radial graft will be positioned in a solu-
tion of heparin and blood until bypass grafting is done. In
both groups all side-branches are clipped with titanium clips.
The techniques are based on, for example, Buxton et al. [51].
The NEO trial 2
The radial artery will be used as a mammario-radial graft
(‘Y-graft’ where the radial artery is anastomosed end-to-
side to the LIMA) or as an aorto-radial graft (free graft
from the aorta) to the coronary artery of choice depend-
ing on which group the patient has been randomised
into. The radial artery can be sequentially anastomosed
onto multiple coronary arteries if so needed. If more
grafts are needed than can be done using the radial ar-
tery, a piece of saphenous vein will be used to the add-
itional grafts. The LIMA will almost always be used as
the primary graft of choice.
Description of graft choice
Patients with multi-vessel disease need more than the
LIMA-LAD graft. The radial artery graft will be used to
primarily left sided coronary arteries, i.e., the so-called
diagonal and marginal branches. If a mammario-radial
anastomosis is done it will also be possible to reach the
end branch of the right coronary vessel named the pos-
terior descending artery (PDA) with the radial artery
graft. If an aorto-radial anastomosis is done and the pa-
tient has a significant stenosis on the right coronary ar-
tery it will not be possible to reach the PDA with the
radial artery. Therefore, a piece of saphenous vein must
be used as a graft to the PDA. In certain cases, where a
significant left coronary main stem stenosis is present
together with an occluded (i.e., >95% stenosis) right cor-
onary artery, the patient will always receive a separate
vein graft to the PDA. This is to secure the patient from
only one inlet supplying the whole heart with blood and
thereby endangering the patient should this trial show
any problems with the mammario-radial anastomosis.
Table 1 Trial interventions
ORAH The skin is incised by scalpel making a 3 cm long incision. The radial artery is dissected free and a vascular clamp is positioned across
the artery. If saturation in the index finger on the non-dominant hand is unchanged and the pulsatile flow measured by pulse-
oximetry is not compromised, the incision is continued from 2 cm proximally to the wrist and all the way to about 4 cm from the
fossa cubiti. The radial artery is dissected free from surrounding tissue by scissors. Side branches are localised and divided by electrical
cutters (‘Cautery Forceps’ manufactured by Starion Instruments). When the artery is totally free it is ligated and divided at both ends.
The incision is closed with Vicryl 3–0 continuous suture in the subcutis and Vicryl 4–0 continuous intradermal suture.
ERAH A 2 to 3 cm long incision is made over the radial artery at the wrist on the non-dominant arm. As with the open procedure a pulse-
oximetry is placed on the arms index finger. The artery is clamped with a vascular clamp thereby insuring the hand is sufficiently
perfused from the ulnary artery. The Maquet Haemopro system (manufactured by MAQUET Gmbh & Co. KG) is then used to dissect
the artery free by ligating the side-branches using the Haemopro’s scopical ligating forceps. To free the artery proximally a stab
incision is made in the fossa cubiti through which the artery is ligated and divided. The incision in the fossa cubiti is only
approximated by Steri-strips but the incision near the wrist is closed with Vicryl 3–0 in the subcutis and Vicryl 4–0 intra-dermally.
Mammario-radial
graft
A mammario-radial graft (Y-graft) is performed before extracorporeal circulation (ECC) is begun. When the mammary artery has
been mobilised and the radial artery harvested, an end-to-side anastomosis is done with the proximal end of the radial artery
being attached to the side of the mammary artery. The anastomosis is sewn with a Prolene 7–0 suture. Free flow through the
anastomosis is checked and papaverin solution is applied to the LIMA and radial artery grafts. ECC is begun, the cross-clamp is
positioned, and cardioplegia is given. The anastomoses of the radial artery to the coronaries are done from the proximal site
going distally. After all radial artery anastomoses are done, the LIMA to LAD anastomosis is performed. After measuring flow in
the grafts using ultrasound, the ECC is weaned according to department procedure. Closure and the remaining hospital stay also
follow department procedures.
Aorto-radial graft An aorto-radial graft (free radial artery graft) is performed when the radial artery graft is sewn directly onto the aorta ascendens.
This is done after all coronary anastomoses have been completed. ECC is still in effect and a sideclamp is positioned on the aorta
ascendens where the cardioplegia cannula is placed. The puncture site for the cardioplegia cannula is also used as the proximal
anastomosis site. The proximal anastomosis is done using a Prolene 6–0 suture. Air is removed by retrograde de-airing removing
the small vascular clamp positioned on the radial artery graft. The cross-clamp is removed after measuring flow in the grafts
using ultrasound and ECC is weaned according to department procedure. Closure and the remaining hospital stay also follow
department procedures.
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intravenously for the first 24 postoperative hours and
amlodipin (calcium antagonist) for 3 months according
to department protocol.
Assessment of outcomes
Overview of outcome measures
As the trial is a 2 × 2 factorial designed trial, the out-
comes are divided into two parts. All outcome measures
are summarised in Table 2 and an overview of the time
schedule for the individual participant can be seen in
Figure 2.
Screening for polyneuropathy
All patients will undergo preoperative screening for poly-
neuropathy. This will be done by a clinical and neuro-
physiological examination using the Utah Early Neuropathy
Scale (UENS) (Table 3) [52] including nerve conduction
studies of the right peroneal and sural nerves. After statis-
tical processing of the primary outcome in the part one ob-
jectives, the mentioned UENS will be used to control for a
bias between the two groups (ERAH versus ORAH) as to
predisposition to a peripheral nerve lesion from a pre-
existing polyneuropathy after randomisation (confounder
control).
The NEO trial 1: primary outcome
Hand function questionnaire (Table 4)
Sum score of hand function questionnaire items 2
through 8. The mean values in the ERAH group will becompared to the mean value in the ORAH group at
3 months after surgery.
The hand function questionnaire has been proposed
by the RAPCO study as a tool to evaluate quality of life
impact by radial artery harvest [53]. This study com-
pared radial artery harvest to vein harvest. There has
also been a quality of life study comparing ERAH versus
ORAH which used a short questionnaire devised by
Medalion as outcome [24]. The questionnaire used in
the RAPCO study seems more precise than the four
questions used by Medalion, which is why it has been
chosen for this trial.
This outcome will be non-blinded. The trial nurse
assigned to the NEO trial will record the responses of
the participants. Source data will be the completed
questionnaire.
The NEO trial 1: secondary outcomes
Neurological deficits
The nerve function will be assessed in joint venture
with the Department of Neurophysiology, Rigshospitalet,
Copenhagen, Denmark, and is planned as follows:
1. Cutaneous sensibility on both forearms and hands
by appraisal of dermatomes. All sensibility modalities
are examined:
a. Cutaneous touch sensibility examined by von
Frey filaments.
b. Deep pain sensibility examined by pressure
algometry.
Figure 2 Examination flow chart.
Table 2 Measurements
Measurement time points Data source Blinding
(x =measuring point, X = outcome endpoint) (Y = yes,
N = no)Preoperatively Before discharge 3 months 1 year
Hand function questionnaire x x X x Questionnaire N
Neurophysiological examination x X Datasheet Y
Clinical neurological examination x X x Case report form (CRF) N
Complication rate x X Database Y
Serious adverse events x x X Register Y
Scar evaluation x X CRF N
Handgrip strength x x x X CRF Y
Muscle function x x x X CRF Y
Vascular function x X Datasheet Y
Graft patency ERAH vs. ORAH X Datasheet Y
Pain scale (LANSS) x x X x CRF N
Cardiac or cerebrovascular events x x X Register Y
Graft patency free radial artery vs. Y-graft X Datasheet N
Cutaneous sensation for cold x x X x CRF N
Neuropathy screening (UENS) x CRF N
Demographic baseline data x CRF N
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Table 3 Utah Early Neuropathy Scale (UENS) [52]
Motor examination:
0 = normal; 2 = weak
Great toe extension Left _____ Right_____
Total both sides (out of 4) __________
Pin sensation:
0 = normal
1 for each segment with reduced
sensation:
Left _____ Right_____
2 for each segment with absent sensation: Left _____ Right_____
Total both sides (out of 24)
Allodynia or hyperesthesia:
0 = normal
1 if present in toes or foot: Left _____ Right_____
Total both sides (out of 2) __________
Large fibre sensation:
0 = normal; 1 = diminished; 2 = absent





Great toe joint position: Left _____ Right_____
Total both sides (out of 8) __________
Deep tendon reflexes:
0 = normal; 1 = diminished; 2 = absent
Ankle: Left _____ Right_____
Total both sides (out of 4) __________
Total score (out of 42) __________
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both arms:
a. Median nerve (digit 2 – wrist); orthodromic
technique.
b. Ulnar nerve (digit 5 – wrist); orthodromic
technique.
c. Superficial sensory branch of the radial nerves
(forearm – wrist); antidromic technique.
d. Lateral antebrachial cutaneous nerve (forearm –
elbow); antidromic technique.e. Medial antebrachial cutaneous nerve (forearm –
elbow); antidromic technique.
3. Motor nerve conduction studies on both arms:
a. Median nerve (wrist – abductor policis brevis
muscle (APB), elbow – APB).
b. Ulnar nerve (wrist – abductor digiti minimi
muscle).
Neurophysiology technicians will perform the nerve
conduction studies and the trial nurse will perform the
quantitative sensory testing.
The outcome measure will be a composite of the 9 dif-
ferent tests performed. Even if one of these tests deterio-
rates significantly from preoperative values, the conclusion
will be that neurological damage has taken place. The pa-
tients will undergo full examination preoperatively and at
3 months.
A significant clinical deterioration on the operated arm
will be:
 von Frey filaments: measurement unit is
milliNewton (mN). The filaments are individually
calibrated to a tolerance range of ±10% of its
nominal force. The normal set includes 12 filaments
(corresponding to 12 successively increasing
nominal values) in the range of 0.25 to 512 mN with
the force increasing by a factor of two from filament
to filament. A significant clinical deterioration is
from one nominal value to ≥1 nominal value
assessed as mean values at four sites on the hand
and forearm.
 Algometry test: A pressure algometer (application
surface 1 cm2) is placed over the palmar base of
metacarpal II on the donor arm and pressure is
applied until the pain threshold is reached.
Corresponding control assessments are made
contralaterally over the palmar base of metacarpal II.
The test measuring unit is kiloPascal (kPa) and the
test is validated for pain assessments over tender-
points in normal muscles [54]. A significant
deterioration is a change in pressure pain threshold
(Δ[control arm – donor arm]) of ≥50 kPa (if the
measurement is <150 kPa) or ≥100 kPa (if the
measurement is ≥150 kPa).
 Sensory nerve conduction study: The peripheral
nerves are activated using a surface stimulation
electrode and the resulting sensory nerve action
potential (SNAP) is recorded with surface
electrodes over the nerve at a point more distal
than or proximal to the stimulation point. The
latency and amplitude of the SNAP is measured and
the conduction velocity is calculated using the
distance between stimulation and recording point.
The results are compared to national multi-centre
Table 4 Hand function questionnaire [53]
1. Right now, my hand and arm appear to be fine. 6. I am concerned about the appearance of my arm scar.
(1) Yes (0) No scar at all
(2) No (1) No concern
2. I feel pain in my arm or hand. (2) Trivial concern
(1) No pain at all (3) Mild
(2) Trivial (4) Moderate
(3) Mild (5) Quite concerned
(4) Moderate (6) Very concerned
(5) Quite severe (7) Extremely concerned
(6) Severe 7. My arm has a scar that causes discomfort.
(7) Severe, unbearable pain (0) No scar at all
2. I feel numbness in my arm or hand. (1) No discomfort
(1) No numbness at all (2) Trivial discomfort
(2) Trivial (3) Mild
(3) Mild (4) Moderate
(4) Mode rate (5) Quite uncomfortable
(5) Quite severe (6) Very uncomfortable
(6) Severe (7) Extremely uncomfortable
(7) Severe, unbearable numbness 8. I have difficulties with daily tasks because of the use of my hand and arm.
4. My arm or hand is swollen. (1) No difficulties at all
(1) No swelling at all (2) Trivial difficulties
(2) Trivial (3) Mild
(3) Mild (4) Moderate
(4) Moderate (5) Quite marked
(5) Quite severe (6) Very marked
(6) Severe (7) Extremely marked
(7) Severe, unbearable swelling Comments: ______________________
5. I have limited use of my hand. 9. Overall, my life is affected by the problems with my hand or arm.
(1) No limitations at all (1) No worse at all
(2) Trivial (2) Trivial life disruptions
(3) Mild (3) Mild
(4) Moderate (4) Moderate
(5) Quite severe (5) Quite marked
(6) Severe (6) Marked
(7) Extremely limited use (7) Life radically worse
Comments: ______________________
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z-scores.
 Motor nerve conduction studies: The compound
motor action potential (cMAP) is recorded from the
muscle belly using surface electrodes in a
pseudomonopolar configuration. The active
electrode is positioned over the motor point of the
muscle belly and the reference electrode is
positioned at a nearby inactive site according to the
laboratory procedures. The electrodes are readjustedto result in a cMAP with an initial negative
deflection and a maximal amplitude. Responses from
supramaximal stimulation at the wrist and in the
median nerve also at the elbow are recorded. Distal
motor latency and amplitude of the maximal cMAP
is measured and motor nerve conduction velocity is
calculated from the distance between stimulation
sites. The results are compared to national multi-
centre age-controlled normal values and reported
as z-scores.
Carranza et al. Trials 2014, 15:135 Page 10 of 18
http://www.trialsjournal.com/content/15/1/135 In both sensory and motor nerve conduction
studies, significant changes in amplitudes of the
responses are defined as a reduction in z-score by a
value of 2.
The outcomes will be non-blinded. The neurophysi-
ology technician will not be blinded towards knowledge
regarding the use of an endoscopic or open technique,
since it will be evident by the scarring. Source data will
be the standardised examination datasheet from the
Department of Neurophysiology and the case report
form (CRF) used by the trial nurse.
Clinical neurological examination of both arms
 Change in cutaneous sensibility from baseline to the
time point 3 months after surgery. Subjective
changes in cutaneous sensibility will be registered
using a map of the forearm and hand on which the
participant can note changes coded by colour. The
change values of the donor arm in the ERAH and
ORAH group will be compared.
The trial nurse will, together with the participants, eva-
luate the change in cutaneous sensibility using a map of
the forearm and hand to mark sensibility changes in the
operated forearm and hand. Cutaneous sensibility will also
be evaluated on non-donor arm to ensure test reliability
and to test for mirror-defects post-surgery.
This outcome will be non-blinded. The trial nurse
assigned to the NEO trial will be trained by the authors
to perform the clinical neurological examinations. Source
data will be the CRF used by the trial nurse.
Complications in the donor arm
 Occurrence of complications at 3 months after
surgery. Complications are defined as a composite of
haematoma formation, wound dehiscence, or
infection registered postoperatively (before
discharge) and 3 months after the operation by the
trial nurse.
This outcome will be non-blinded. The trial nurse
assigned to the NEO trial will register the complications
occurring in the operated sites of ERAH and ORAH par-
ticipants. Source data will be database data from the sur-
gical complication register.
The NEO trial 1: exploratory outcomes
The following outcomes are ‘exploratory’, as we have not
been able to perform power calculations due to none or
very limited data from previous trials or studies.Serious adverse events
 Occurrence of the following serious adverse events
at time point one year after surgery: reoperation for
bleeding; revascularisation; myocardial infarction;
stroke; or death (see section ‘Safety’).
This outcome will be blinded. The data will be col-
lected directly from the Danish Patient Register using
the participant’s civil registration number.Scar evaluation
 Stony Brooke Scar Evaluation Score [55] (Table 5) at
one year after surgery. Comparison of mean scores
in the ERAH and the ORAH group.
This outcome will be non-blinded. The trial nurse
assigned to the NEO trial will be trained in and perform
the scar evaluation. The data source will be the CRF.Handgrip strength
Maximal handgrip strength one year postoperatively
(Table 6).
A hand dynamometer will be used to measure the
maximum isometric hand and forearm muscle strength
on both hands with the elbows flexed. Three consecutive
tests will be done with 15 seconds of recovery time be-
tween tests; this test has been validated [56]. Measuring
unit is kilograms and rating of the test is seen in Table 6.
This outcome will be semi-blinded. An independent
health care professional who performs the handgrip
strength measurements will be blinded by covering the
skin of the donor arm to disguise the harvest technique
used. The data source will be the CRF.Muscular function
 The following muscles will be rated according to the
Oxford Scale for grading muscle strength (Table 7)
at one year postoperatively: abductor pollicis brevis
muscle; abductor digiti minimi muscle; 1st
interosseus dorsalis muscle; flexor digitorum
profundus muscle to finger 2 and 5; and extensor
digitorum communis muscle.
The rating scale is sometimes also referred to as ‘Medical
Research Council Scale for Muscle Strength’. This out-
come will be semi-blinded. An independent health care
professional will perform the muscle strength evaluation
blinded by covering the donor arm to disguise the harvest
technique used. The data source will be the CRF.
Table 5 Stone Brook Scar Evaluation Scale [55]
Scar category No. of
point
Width >2 mm 0
≤2 mm 1




Colour Darker than surrounding skin (red, purple,
brown or black)
0







Overall appearance Poor 0
Good 1
Table 7 Grading of muscle strength (Oxford Scale)
Grade 0 No muscle movement
Grade 1 Muscle movement without joint motion
Grade 2 Moves with gravity eliminated
Grade 3 Moves against gravity but not resistance
Grade 4 Moves against gravity and light resistance
Grade 5 Normal strength
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 Mean score of each of the hand function
questionnaire items 2 through 8 (Table 4). The
mean values in the ERAH group will be compared
to the mean value in the ORAH group at 3 months
after surgery.
Neurological deficits single tests
 Occurrences of neurological deficits at 3 months
after surgery. The deterioration of each of the
clinical neurological tests is defined as a secondary
outcome.
MSCT evaluation of graft patency
 Patency of the graft at one year after the surgery.
The patency will be divided into perfect patency,
incomplete patency, string sign, and occluded
according to assessment by MSCT, and the ERAH
will be compared to the ORAH group.Table 6 Rating intervals of handgrip strength
Rating Males Females
(lbs) (kg) (lbs) (kg)
Excellent >141 >64 >84 >38
Very good 123–141 56–64 75–84 34–38
Above average 114–122 52–55 66–74 30–33
Average 105–113 48–51 57–65 26–29
Below average 96–104 44–47 49–56 23–25
Poor 88–95 40–43 44–48 20–22
Very poor <88 <40 <44 <20The MSCT allows for assessment of cardiac structures
and both 16-slice and 64-slice scanners have been vali-
dated for assessing the graft patency after CABG [57,58].
The patients included in the study are scanned using a
320-slice scanner (Toshiba Aquilion ONE, Japan). The
scanning protocol is as follows: Gantry rotation time
350 ms, detector collimation 0.5 × 320. Tube voltage and
current are chosen based on the patient’s body mass
index ranging between 100 and 120 kV and between 280
and 500 mA. An intravenous contrast media (Visipaque
320 mg/mL, GE Healthcare, UK) is infused using a flow
rate of 6 mL/s followed by a saline chaser. The contrast
dye volume used is individually calculated according to
patient body mass index (100–130 mL). Image interpret-
ation is performed using commercially available software
(Vitrea, version 3.0.1, Vital Images, USA). Grafts are
evaluated by two experts in cardiac MSCT blinded to
the patient’s randomisation status in the trial. MSCT is
performed at the department of radiology one year after
the operation.
This outcome will be blinded. Two employees from the
Department of Cardiology and Radiology will do the inter-
pretation of MSCT scans for patency, without knowledge
of whether the radial artery has been harvested by endo-
scopic or open techniques.
Neuropathic pain symptoms and signs
 The Leeds assessment of neuropathic symptoms and
signs (LANNS) pain scale [59] at 3 months after
surgery (Table 8). The Danish version of this
assessment is tested to have a cut-off value at ≥12.
This outcome will be non-blinded. The trial nurse
assigned to the NEO trial will record the responses of
the participants. The data source will be the CRF.
Vascular function
The vascular function will be assessed by single photon
emission computed tomography (SPECT) of the hand.
The technique used is 99mTechnetium sestamibi imaging
which is commonly known as a ‘MIBI scan’ and is most
often used for myocardial perfusion [60]. 99mTechnetium
sestamibi is a lipophilic cation which when injected dis-
tributes accordingly to the blood perfusion. Using a
Table 8 Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) [59]
A. PAIN QUESTIONNAIRE
• Think about how your pain has felt over the last week.
• Please say whether any of the descriptions match your pain exactly.
1) Does your pain feel like strange, unpleasant sensations in your skin? Words like pricking, tingling, and pins and needles might
describe these sensations
a. NO – My pain doesn’t really feel like this…………………………………………………………………..………………………………(0)
b. YES – I get these sensations quite a lot……………………………………………………………….…….…………………..….………(5)
2) Does your pain make the skin in the painful area look different from normal? Words like mottled or looking more red or pink might
describe the appearance.
a. NO – My pain doesn’t affect the colour of my skin……………………………………………………………………….….……………(0)
b. YES – I’ve noticed that the pain does make my skin look different from normal………………….………………..…….…………….…(5)
3) Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant sensations when lightly stroking the skin, or
getting pain when wearing tight clothes might describe the abnormal sensitivity.
a. NO – My pain doesn’t make my skin abnormally sensitive in that area….………………………………………………….……….……(0)
b. YES – My skin seems abnormally sensitive to touch in that area………………………………………….…….……….……….….….…(3)
4) Does your pain come on suddenly and in bursts for no apparent reason when you’re still? Words like electric shocks, jumping and
bursting describe these sensations.
a. NO – My pain doesn’t really feel like this…. ………….………………………………………………….….……………………………..(0)
b. YES – I get these sensations quite a lot…………………………………………………………….…….…………………..…………….(2)
5) Does your pain feel as if the skin temperature in the painful area has changed abnormally? Words like hot and burning describe these
sensations.
a. NO – I don’t really get these sensations………………………………………………….……….……………………..…………………(0)
b. YES – I get these sensations quite a lot……………………………………………….……….………………………..………………….(1)
B. SENSORY TESTING
Skin sensitivity can be examined by comparing the painful area with a contralateral or adjacent non-painful area for the presence of allodynia and an
altered pin-prick threshold (PPT).
1) ALLODYNIA
Examine the response to lightly stroking cotton wool across the non-painful area and then the painful area. If normal sensations are experienced
in the non-painful site, but pain or unpleasant sensations (tingling, nausea) are experienced in the painful area when stroking, allodynia is present.
a. NO, normal sensation in both areas………………………………………………….….………………………………......………………(0)
b. YES, allodynia in painful area only………………………………………………………………….….………………….….….….………(5)
2) ALTERED PIN-PRICK THRESHOLD
Determine the pin-prick treshold by comparing the response to a 23 gauge (blue) needle mounted inside a 2 mL syringe barrel placed gently on
to the skin in the non-painful and then in the painful areas.
If a sharp pin-prick is felt in the non-painful area, but a different sensation is experienced in the painful area, e.g., none/blunt only (raised PPT) or
a very painful sensation (lowered PPT), an altered PPT is present.
a. NO, equal sensation in both areas…………………………………………………………………….….……………….….….….………(0)
b. YES, altered PPT in painful area…………………….………………………………………….….…..….….……….….…..…………….….(3)
SCORING:
Add values in parentheses for sensory description and examination findings to obtain overall score.
TOTAL SCORE (maximum 24)…………….
If score <12, neuropathic mechanisms are unlikely to be contributing to the patient’s pain.
If score ≥12, neuropathic mechanisms are likely to be contributing to the patient’s pain.
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emitted by the decay of 99mTechnetium sestamibi. When
injected after stress exercise a possible insufficiently per-
fused area will be evident.A total of 100 patients will be randomly included in
the 99mTechnetium sestamibi imaging examination of
the hand; 50 patients will come from each of the ERAH
and ORAH groups. There will be no consideration taken
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mammario-radial groups. These patients will preopera-
tively and 3 months postoperatively be examined for
vascular function in the donor hand comparing 3-month
values to baseline values. Values will also be compared
to the non-donor hand. The MIBI scan will show if there
is any difference in perfusion after removal of the radial
artery. There have been no previous studies examining
the hand with MIBI scans, so the examinations aim to
validate the technique in this setting. We propose that
the ratio between measurements on thenar (base of the
thumb) and on hypothenar (base of the little finger) can
be a reliable indicator of hypoperfusion in the hand after
removal of the radial artery.
Staff employed at The Department of Clinical Physi-
ology, Nuclear Medicine, & PET, will perform the MIBI
scans.
The outcome will be the quantitative difference in
blood-flow to the hand, measured using the MIBI scan.
Time point will be 3 months after surgery. The measur-
ing unit is counts/cm2 that may be converted to estimate
of Bq/cm2.
Since no previous similar test has been found in the
literature search it is not possible to do pretrial power
calculations.
This outcome will be blinded. The Department of
Clinical Physiology, Nuclear Medicine, & PET will per-
form the exams and interpretations without knowledge
of whether the radial artery has been harvested by endo-
scopic or open techniques. The data source will be a
datasheet from the Department of Clinical Physiology.
The NEO trial 2: primary outcome
Occurrence of cardiac and cerebrovascular events
 Occurrence of one of the following cardio- or cere-
brovascular events: all-cause mortality, myocardial
infarction, target vessel revascularisation, or stroke
at one year postoperatively.
The outcome will be blinded. The data will be col-
lected directly from the Danish Patient Register using
the participant’s civil registration number. We are well
aware of the exploratory nature of this outcome (please
see below).
The NEO trial 2: exploratory outcome
MSCT evaluation of graft patency
Same technique and procedure will be used as men-
tioned earlier in the text.
Outcome measure will be patency of the graft at one
year after surgery. The patency will be divided into per-
fect patency, occluded, incomplete patency, and string
sign according to assessment by MSCT.The outcome will be non-blinded. Two employees
from the Department of Cardiology and Radiology will
do the interpretation of MSCT scans for patency, but it
will be evident on the MSCT which proximal anasto-
mosis site is used.
Sample size
The NEO trial 1
We are planning a trial of a continuous response vari-
able (hand function) from independent control and ex-
perimental participants with approximately one control
per experimental participant. In a previous study, the
response within each participant group was normally
distributed with a standard deviation of 8 [53]. The tar-
geted objective is, as mentioned, the hand function
questionnaire (Table 4). If the true difference in the ex-
perimental and control means is 3, we will need to study
150 experimental participants and 150 control partici-
pants to be able to reject the null hypothesis that the
population means of the experimental and control
groups are equal with probability (power) 90%. The type
I error probability associated with this test of this null
hypothesis is 5%. In total, we thus need to include 300
participants.
The NEO trial 2
One case-control study found an event-free survival at
12 months of 97% using arterial revascularisation
compared to 67% using venous revascularisation [47].
Another case-control study showed a survival free of
cardiac event or death at 2.5 years of 11% for free grafts
versus 17% for Y-grafts, but the risk of re-angina was
6.6% in the free graft group versus 4.6% in the Y-graft
group [45]. No studies showed exactly what difference
in occurrence of cerebrovascular composite outcomes
could be expected between free grafts and Y-grafts, but a
randomised clinical trial comparing arterial Y-graft with
free saphenous vein grafts found significantly lower
cardiac event-free survival at less than 2 years with a dif-
ference of about 20% events in free grafts versus 5% in
Y-grafts [47]. Considering these studies, we expect max-
imally a difference in occurrence of cardio or cerebro-
vascular outcomes at one year postoperatively of 5%
(15% in mammario-radial group vs. 10% in aorto-radial
group).
We are planning a trial with approximately 150 experi-
mental participants and 150 control participants. We
will then only have a power of 25.7% to detect the differ-
ence of 15% composite outcomes in mammario-radial
group versus 10% in aorto-radial group using a type I
error probability of 5%. We will use an uncorrected χ2
statistic to evaluate this null hypothesis. Therefore,
the NEO trial 2 will only be an exploratory trial to plan
the size of a future randomised trial concerning the
Carranza et al. Trials 2014, 15:135 Page 14 of 18
http://www.trialsjournal.com/content/15/1/135occurrence of cardiac and cerebrovascular events using
mammario-radial versus aorto-radial anastomosis.
Power estimations for secondary outcomes
Neurological deficits
Assuming a difference in occurrences of neurological
deficits of 30% versus 15% in the two groups, using a
type I error of 5% and by including 300 participants, we
will have 88% power to detect a difference between the
two groups.
Clinical neurological examination of both arms
Assuming a difference in cutaneous sensibility of 30% ver-
sus 15% in the two groups, using a type I error of 5% and
by including 300 participants, we will have 88% power to
detect a difference between the two groups.
Complications
Assuming a difference in complications of 7% versus 1%
in the two groups, using a type I error of 5% and by in-
cluding 300 participants, we will have 76% power to de-
tect a difference between the two groups.
Data collection
Method
Data will be collected in the CRF preoperatively and
postoperatively at 3 months and 1 year after surgery.
The CRF will be paper-based and will be entered into a
digital database using OpenClinica software by two inde-
pendent persons entering the same data independently.
Data will be collected from interviews and examinations
of the participants, from the surgical database (named
‘PATS’), from the electronic patient journal system
(named ‘OPUS’), and from the Danish national patient
database (named ‘Landspatientregistret’).
Timing
Before discharge, 3 months, and 1 year after the surgery,
these patients will be clinically evaluated for a haema-
toma formation, infection, neurological deficits, and vas-
cular dysfunction and their scar will be scored by a
clinical examination. On the day before surgery and
3 months postoperatively, all patients will undergo a
motor and sensory nerve conduction study. A subgroup
of 100 patients will be selected randomly with 50% of
patients in each of the ERAH and ORAH groups. This
subgroup will undergo physiological examination of vas-
cular function in the hand preoperatively and 3 months
after surgery. Before including the first patients, a pilot-
study of 5 patients undergoing physiological examination
of vascular function will be done to evaluate examin-
ation technique implementation. In the vascular study
group the opposite non-operated arm will act as control.
MSCT will be conducted 1 year after surgery in all 324patients with blinded evaluation of the secondary out-
come (graft patency evaluation by 320 slice-MSCT).
Figure 1 shows a flowchart over the randomisation pro-
cedure used in this trial.
See Table 2 for the planned collection of outcome data.
Attrition
To avoid trial attrition we have chosen short-term out-
come of one year. The close and personal contact with
the trial nurse also lessens risk of loss to follow-up.
Trial participants will find it beneficial to follow 3 month
and 1 year postoperative visits for optimal treatment
and controls not offered to non-NEO trial participants.
The trial nurse will directly contact participants if they
miss an outpatient visit. Likewise, the trial nurse will
keep contact information of the participants up to date
after every contact.
Statistical methods
Statistical analyses will be conducted blinded by an in-
dependent statistician from the Copenhagen Trial Unit
according to a detailed statistical analysis plan that
will be developed before all the data are collected.
The statistical analysis plan will thereby have been
specified independently of the results. The statistical
analysis will also take into account interventionist risk
of bias.
The NEO trial 1 and the NEO trial 2 objectives do not
overlap, so we do not need any adjustment for multipli-
city and it will be possible to raise different conclusions
for any one of the objectives.
The detailed statistical analyses will be described else-
where. In brief, the analyses will be intention-to-treat.
The primary analyses will, for all outcomes, be adjusted
for the stratification variables (age and sex). Secondly,
we will present unadjusted analyses.
Analysis of continuous outcomes
Continuous outcomes will be described as mean, mean
difference, median, standard deviation, and range. The
general linear model (ANCOVA and ANOVA) will be
used to compare the results between the intervention
groups.
Analysis of dichotomous outcomes
Dichotomous outcomes will be summarised as numbers,
percentages, odds ratios, and 95% confidence intervals.
Logistic regression will be used to compare the interven-
tion groups.
Non-parametric tests
The non-parametric van Elteren test will be used if the
assumptions behind the parametric methods are not
fulfilled.
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The thresholds for significance will be assessed according
to the 5-point procedure suggested by Jakobsen et al. [61].
Missing outcomes
If more than 5% of the primary and secondary outcomes
are missing, multiple imputation will be used in the ana-
lysis of the primary and secondary outcomes (STATA
13). The imputation result will be considered the pri-
mary overall result.
Screening for polyneuropathy
A statistical analysis comparing the UENS between
ERAH and ORAH groups will be done. An analysis of
the standardised amplitudes of motoric and sensory
answers (z-scores) between the two groups will be
diagnostic for polyneuropathy if two or more nerves
(medianus, ulnaris, peroneus, suralis) have a z-score of
less than 2.
Ethics and trial registration
The trial protocol has been submitted to the Danish re-
gional ethics committee for the Capital Region and has
been approved under the case number: H-3-2012-116 in
December of 2012. The planned data safety and registra-
tion procedures have been approved by the Danish Data
Protection Agency under the case number: 2007-58-
0015/30-0838. The trial is registered at ClinicalTrials.gov
(Identifier: NCT01848886).
Ethical justification
This trial will add to the evidence base regarding which
ways to harvest radial artery grafts and which way to
anastomose these grafts in the patients undergoing
CABG. All patients will receive verbal and written infor-
mation about the trial well before the operation is
planned and they will all have signed an informed con-
sent form before being included in the trial.
Radiation exposure
 SPECT of the hands: Participants will be exposed to
approximately 6 mSv corresponding to about 2 years
of background radiation [62]. Two exams will be
done resulting in 100 participants exposed to
approximately 12 mSv of radiation or about 4 years
of background radiation.
 MSCT: Approximately 7 mSv is the radiation
exposure when doing the cardiac CT angiography.
This corresponds to the same amount of radiation
exposure when undergoing a classical angiography.
All 300 participants will be exposed to this exam
equivalent of less than 3 years of background
radiation.A participant can therefore at the most be exposed to
19 mSv of radiation corresponding to less than 7 years
of background radiation; 100 participants will be ex-
posed to the maximum radiation dose, since they are in-
cluded in the SPECT group, but the remaining 200
participants will be exposed to 7 mSv, i.e., less than
3 years of background radiation.
The risk of cancer secondary to radiation exposure
will, in the 100 participants (SPECT and MSCT), at the
most rise from 30,000 deaths related to cancer to 30,095
deaths related to cancer per 100,000 persons exposed
and for the remaining 300 participants (MSCT only) it
will at the most rise from 30,000 deaths related to cancer
to 30,035 deaths related to cancer per 100,000 persons
exposed. These numbers are according to The Danish
Board of Health [63].
Pain and discomfort
 The neurophysiological examination can give rise to
mild pain and some discomfort during the
examination. The pain is expected to be visual
analogue scale level 3 to 4.
Participants undergoing ERAH are expected to have
less pain than ORAH [19]. Since ORAH is presently pri-
mary choice of radial artery harvest no participants in
the trial will experience a higher degree of pain attrib-
uted to their inclusion in the trial.
Discussion
The NEO trial will be able to compare the endoscopic
with the open surgery radial artery harvesting tech-
niques. Only three smaller randomised trials have been
conducted trying to assess the patency and complica-
tions in ERAH versus ORAH. The NEO trial 1 will be
able to assess if there is significantly less neurological
complications when harvesting the radial artery with an
endoscopic technique than by an open technique. We
may find a tendency towards less haematoma formation
and fewer infections in the ERAH than in the ORAH
groups since it has been shown in other studies. No sig-
nificant decrease in the vascular supply in the donor
arms compared to non-donor arms has been indicated
in previous studies, but the NEO trial 1 will try to assess
if there could be a relative ischaemic state after radial ar-
tery harvest using a new diagnostic test. Particularly, any
neurological deficits can limit the hand function of the
patients postoperatively and it is important to try to get
a clearer picture of this. The NEO trial 1 will also exam-
ine if there is any difference in patency in ERAH partici-
pants versus ORAH participants. This is an important
point to be addressed since, if there is any difference, it
can have severe consequences for the patients. All these
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future of endoscopic harvest of the radial artery. We be-
lieve and hypothesise that the technique will be benefi-
cial to the patients and will render the endoscopic
procedure as the preferred technique when harvesting
the radial artery for arterial revascularisation.
Another point of interest that the NEO trial 2 tries to
enlighten is the optimal site of the proximal anastomosis
when using the radial artery as a bypass graft. There are
no randomised clinical trials telling us if aorto-radial or
mammario-radial anastomosis is the best choice. Well
aware that the NEO trial 2 does not have the power to
show a significant difference when measuring major cere-
brovascular events, we hope to get enough data to find a
likely sample size for another randomised trial dedicated
to this question. If this trial shows the mammario-radial
technique being non-inferior to the aorto-radial technique,
it will also be of great advantage. The mammario-radial
technique has the great advantages of avoiding the side-
clamp and the possibility to revascularise all three coron-
ary vessels with a minimum of grafts required.
The NEO trial has the great advantage of using a 2 × 2
factorial design. This enables the trial to examine the
benefits and harms of two different surgical strategies in
the setting of one randomised clinical trial. The disad-
vantage of the trial is the exploratory nature when exam-
ining the two possible anastomotic sites of the radial
artery. The complexity and elaborate neurological exam-
inations including both objective tests and subjective an-
swers on questionnaires is a major advantage of the
NEO trial. This will make us able to both evaluate pa-
tient related parameters, such as quality of life, as well as
factual complications comparing ORAH with ERAH. In
an evolving field of modern cardiac surgery using arterial
revascularisation and endoscopic technique, this trial
will contribute with important facts necessary for opti-
mising patient treatment.
Limitations
There will be a partial lack of blinding since the surgeon
and the patient cannot be blinded as to which oper-
ational technique has been used. All measurements
available for blinding will be blinded. There will be an
evaluator risk of bias in the part one objectives since the
trial nurse cannot be blinded.
Dissemination policy – trial results
All trial results and de-personalised individual partici-
pant data, whether positive, negative, or neutral, will end
up in the public domain, preferably in peer-reviewed
publications and in a public trial data repository. The
trial is registered at clinicaltrials.gov, which ensures the
results are public domain in accordance to the Consort
Statement [64].Dissemination policy – authorship
Authorship will be determined according to the guide-
lines from the International Committee for Medical
Journal Editors.
Dissemination policy – reproducible results
The de-identified and de-personalised data will be
uploaded to clinicaltrials.gov within 2 years after com-
pletion of follow-up of the last patient.
Trial status
We started screening and randomising patients on the
16th of May 2013. By the 15th of March 2014 we have
randomised and operated the first 50 patients and
screened >1,000 patients.
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